| 生物活性 |
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).
|
|---|---|
| 分子量 |
146.32 kDa
|
| CAS号 |
1322627-61-1
|
| 中文名称 |
Ligelizumab
|
| 运输条件 |
Shipping with dry ice.
|
| 储存方式 |
Store at -20˚C
|
纯度： 99%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet